Successful foscarnet therapy for mucocutaneous infection with herpes simplex virus in a recipient after unrelated bone marrow transplantation

T. Iino, H. Gondo, Y. Ohno, H. Minagawa, H. Iwasaki, Toru Maruyama, H. Nakashima, Y. Niho

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

A 36-year-old Japanese man who received an unrelated bone marrow transplant (BMT) developed severe mucocutaneous infection with herpes simplex virus (HSV) type 1 during oral acyclovir prophylaxis. The lesions progressed despite treatment with intravenous acyclovir and vidarabine. The HSV isolates were sensitive to acyclovir, vidarabine and foscarnet in vitro, but peripheral CD3- or CD19-positive cells were barely detectable even 4 months after transplant. A 12-day course of treatment with foscarnet led to a rapid improvement. Foscarnet therapy should be considered for all severe HSV infections following BMT, regardless of whether or not the HSV isolates are sensitive to acyclovir.

Original languageEnglish
Pages (from-to)1185-1188
Number of pages4
JournalBone Marrow Transplantation
Volume18
Issue number6
Publication statusPublished - Dec 1 1996

Fingerprint

Foscarnet
Acyclovir
Simplexvirus
Bone Marrow Transplantation
Vidarabine
Infection
Transplants
Bone Marrow
Human Herpesvirus 1
Virus Diseases
Therapeutics

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

Cite this

Successful foscarnet therapy for mucocutaneous infection with herpes simplex virus in a recipient after unrelated bone marrow transplantation. / Iino, T.; Gondo, H.; Ohno, Y.; Minagawa, H.; Iwasaki, H.; Maruyama, Toru; Nakashima, H.; Niho, Y.

In: Bone Marrow Transplantation, Vol. 18, No. 6, 01.12.1996, p. 1185-1188.

Research output: Contribution to journalArticle

Iino, T. ; Gondo, H. ; Ohno, Y. ; Minagawa, H. ; Iwasaki, H. ; Maruyama, Toru ; Nakashima, H. ; Niho, Y. / Successful foscarnet therapy for mucocutaneous infection with herpes simplex virus in a recipient after unrelated bone marrow transplantation. In: Bone Marrow Transplantation. 1996 ; Vol. 18, No. 6. pp. 1185-1188.
@article{3e19993e05bf4e04a39e69843aa4b9d7,
title = "Successful foscarnet therapy for mucocutaneous infection with herpes simplex virus in a recipient after unrelated bone marrow transplantation",
abstract = "A 36-year-old Japanese man who received an unrelated bone marrow transplant (BMT) developed severe mucocutaneous infection with herpes simplex virus (HSV) type 1 during oral acyclovir prophylaxis. The lesions progressed despite treatment with intravenous acyclovir and vidarabine. The HSV isolates were sensitive to acyclovir, vidarabine and foscarnet in vitro, but peripheral CD3- or CD19-positive cells were barely detectable even 4 months after transplant. A 12-day course of treatment with foscarnet led to a rapid improvement. Foscarnet therapy should be considered for all severe HSV infections following BMT, regardless of whether or not the HSV isolates are sensitive to acyclovir.",
author = "T. Iino and H. Gondo and Y. Ohno and H. Minagawa and H. Iwasaki and Toru Maruyama and H. Nakashima and Y. Niho",
year = "1996",
month = "12",
day = "1",
language = "English",
volume = "18",
pages = "1185--1188",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Successful foscarnet therapy for mucocutaneous infection with herpes simplex virus in a recipient after unrelated bone marrow transplantation

AU - Iino, T.

AU - Gondo, H.

AU - Ohno, Y.

AU - Minagawa, H.

AU - Iwasaki, H.

AU - Maruyama, Toru

AU - Nakashima, H.

AU - Niho, Y.

PY - 1996/12/1

Y1 - 1996/12/1

N2 - A 36-year-old Japanese man who received an unrelated bone marrow transplant (BMT) developed severe mucocutaneous infection with herpes simplex virus (HSV) type 1 during oral acyclovir prophylaxis. The lesions progressed despite treatment with intravenous acyclovir and vidarabine. The HSV isolates were sensitive to acyclovir, vidarabine and foscarnet in vitro, but peripheral CD3- or CD19-positive cells were barely detectable even 4 months after transplant. A 12-day course of treatment with foscarnet led to a rapid improvement. Foscarnet therapy should be considered for all severe HSV infections following BMT, regardless of whether or not the HSV isolates are sensitive to acyclovir.

AB - A 36-year-old Japanese man who received an unrelated bone marrow transplant (BMT) developed severe mucocutaneous infection with herpes simplex virus (HSV) type 1 during oral acyclovir prophylaxis. The lesions progressed despite treatment with intravenous acyclovir and vidarabine. The HSV isolates were sensitive to acyclovir, vidarabine and foscarnet in vitro, but peripheral CD3- or CD19-positive cells were barely detectable even 4 months after transplant. A 12-day course of treatment with foscarnet led to a rapid improvement. Foscarnet therapy should be considered for all severe HSV infections following BMT, regardless of whether or not the HSV isolates are sensitive to acyclovir.

UR - http://www.scopus.com/inward/record.url?scp=0030444532&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030444532&partnerID=8YFLogxK

M3 - Article

C2 - 8971394

AN - SCOPUS:0030444532

VL - 18

SP - 1185

EP - 1188

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 6

ER -